Our Leadership

Dr. Tom Lin (Yu-Hsin Lin) is the Founder, Chairman, and Chief Executive Officer of Belite Bio. Dr. Lin is also the Founder of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder. Prior to founding Belite Bio, Dr. Lin was executive officer of several biotech companies, including Lin BioScience, Inc. Dr. Lin received his master’s degree in Medicine and PhD in Medicine from University of Sydney, and his MBA from Columbia University, London Business School, and University of Hong Kong.

Mr. Hao-Yuan Chuang has served as the Chief Financial Officer of our Company since April 2020 and Director of Belite Bio since November 2021. Prior to joining Belite Bio, Mr. Chuang served as Chief Financial Officer of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder, Investment Director of Suning International Limited, and Portfolio Manager of The People’s Insurance Company (Group) of China Limited (HKG: 1339). Mr. Chuang received his MBA from Columbia University, London Business School, and the University of Hong Kong. Mr. Chuang is also a Chartered Financial Analyst and Financial Risk Manager.

Kelly Kilpatrick has served as Chief Commercial Officer of Belite Bio since January 2026. She brings nearly three decades of commercial leadership experience across the biopharmaceutical industry, with deep expertise in commercial strategy and product launches, including experience in ophthalmology and rare disease. Prior to joining Belite Bio, Ms. Kilpatrick was Senior Vice President, Head of U.S. Commercial – Ocular Gene Therapy at Spark Therapeutics (a Roche company), where she led the U.S. ocular commercial organization. Earlier in her career, she held leadership roles at Regeneron Pharmaceuticals and GSK spanning commercial, sales, and market access. Ms. Kilpatrick received her bachelor’s degree in Biochemistry from Rochester Institute of Technology.

Dr. Nathan L. Mata has served as the Chief Scientific Officer of Belite Bio since November 2021. Prior to joining Belite Bio, Dr. Mata was the principal consultant of clinical development sector of Halloran Consulting Group, clinical research and operations consultant of Kubota Vision Inc. (formerly Acucela Inc.), Chief Operating Officer and Director of R&D of Trethera Corporation, and Vice President of R&D of Sirion Therapeutics. Dr. Mata received his master’s degree in Biochemistry and PhD in Neurobiology from University of Texas at San Antonio.

Prof Hendrik Scholl, MD, has served as the Chief Medical Officer of Belite Bio since September 2024. He is a clinically active retinal expert with more than two decades of expertise in treating retinal diseases, including Stargardt disease and age-related macular degeneration. Dr. Scholl served as the founding and scientific co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Chair of the Department of Ophthalmology of the University Hospital Basel. He currently serves as President of the European Vision Institute (EVI), Chairman of EVICR.net and its Expert Committee on Retinal Dystrophies, and Founder and President of ARVO-SWISS. In academia, Dr. Scholl has held leadership roles at key institutions, notably as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School, where he also led the Retinal Degeneration Clinic and the Visual Neurophysiology Service. Dr. Scholl is the coordinating principal investigator of the largest natural history study of Stargardt disease (ProgStar Study). He holds an honorary doctorate from Semmelweis University in Budapest, Hungary, and is Adjunct Professor at the Medical University of Vienna, Austria. Dr. Scholl graduated from the Eberhard-Karls-University Tübingen, Germany, with a Doctor of Medicine and Master of Arts. He was awarded a research fellowship from the German Research Foundation (DFG) at Moorfields Eye Hospital and Institute of Ophthalmology, University College London (UCL), United Kingdom, and later a DFG Heisenberg Professorship for Macular Diseases at the Eye Clinic of the Rheinische Friedrich-Wilhelms-University Bonn, Germany.